Dental laser supplier BIOLASE Inc (NASDAQ:BIOL) reported on Tuesday the receipt of US the Food and Drug Administration (FDA) regulatory clearance for the Epic Hygiene laser for Laser Bacterial Reduction (LBR) therapy indication.

US FDA approval for the company's Epic Hygiene laser allows for the early management of periodontal disease utilizing laser light energy to reduce bacteria and thus decreasing inflammation and enhancing periodontal health.

Designed by dental hygienists, the Epic Hygiene laser provides the dental hygienist community with more access to the advantages of laser technology as well as allows to perform gentler, highly effective treatments for bacterial reduction and managing periodontal disease.

The company stated that the Epic Hygiene laser has received clearance for the removal of highly inflamed edematous tissue affected by bacteria penetration of the pocket lining and junctional epithelium.